Please ensure Javascript is enabled for purposes of website accessibility

Coronavirus Vaccine Candidates Could Enter Clinical Trials in April

By Cory Renauer - Mar 12, 2020 at 3:30PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A top U.S. health official says the first human studies with potential new COVID-19 vaccines could begin in a few weeks.

A top U.S. official speaking to Congress on Thursday expressed confidence that potential coronavirus vaccines would be ready for in-human testing in record time.

Previously, Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases (NIAID), suggested it would be two to three months before researchers injected the first people with experimental vaccines against the SARS-CoV-2 coronavirus.

COVID-19 blood sample

Image source: Getty Images.

Record time 

Fauci was not specific about which experimental coronavirus vaccine he expected would be the first into human trials, but we do know that the National Institutes of Health and Moderna (MRNA 3.73%) have been working together to develop one for weeks now. Moderna shipped batches of mRNA-1273 to the NIAID on Feb. 24.

Fauci also stressed that getting a vaccine candidate into clinical trials doesn't mean that the vaccine will be available to the public quickly. Injecting strands of genetic material into tens of millions of people isn't something the FDA's going to allow until it's clear whether or not it works and is safe -- and it will take a year to 18 months to find that out.

Something different

Moderna's COVID-19 vaccine candidate is just one of many in the pre-clinical development stage. But despite a crowded field, mRNA-1273 has a chance to stand out. 

Instead of injecting patients with proteins found on the surface of viruses, Moderna's vaccines are strands of mRNA that coax a person's own cells to start producing proteins found on the surface of viruses. 

Moderna's working on a long list of vaccines against infectious diseases, but none have proven themselves in pivotal studies yet.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Moderna, Inc. Stock Quote
Moderna, Inc.
MRNA
$155.54 (3.73%) $5.59

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
316%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/06/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.